Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Kalaris Therapeutics ( (KLRS) ) has issued an announcement.
On April 3, 2025, Kalaris Therapeutics, Inc. announced the election of Leone Patterson to its Board of Directors as a Class III director, with her term set to expire at the 2026 annual meeting of stockholders. Ms. Patterson was also appointed as Chair of the Audit Committee, joining Anthony Adamis, M.D., and Morana Jovan-Embiricos, Ph.D. The company plans to implement a new Non-Employee Director Compensation Program, under which Ms. Patterson will receive compensation for her board and committee service. Additionally, she will enter into an indemnification agreement with the company, ensuring protection against certain legal expenses related to her directorial role.
More about Kalaris Therapeutics
YTD Price Performance: -23.40%
Average Trading Volume: 25,503
Technical Sentiment Signal: Strong Buy
Current Market Cap: $123.9M
For an in-depth examination of KLRS stock, go to TipRanks’ Stock Analysis page.